Story perspectives

Judge Calls FDA Mifepristone Restrictions Arbitrary, Orders Review

7/25/2026

Summary

Story summary

U.S. District Judge Robert S. Ballou ruled FDA’s mifepristone restrictions arbitrary and capricious.
He ordered President Donald Trump’s administration to review and possibly remove the restrictions.
Ballou remanded the 2023 REMS, noting mortality of 0.65 per 100,000 abortions, lower than penicillin’s 2 per 100,000.
President Nancy Northup and Health Alliance President Amy Hagstrom Miller called it a win for science, noting it removes paperwork and lets clinics focus on care.

1 of 1

Story summary

U.S. District Judge Robert S. Ballou ruled FDA’s mifepristone restrictions arbitrary and capricious.
He ordered President Donald Trump’s administration to review and possibly remove the restrictions.
Ballou remanded the 2023 REMS, noting mortality of 0.65 per 100,000 abortions, lower than penicillin’s 2 per 100,000.
President Nancy Northup and Health Alliance President Amy Hagstrom Miller called it a win for science, noting it removes paperwork and lets clinics focus on care.